Skip to main content

Table 4 Treatment-related adverse events (≥0.4%) according to patient age

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Adverse event, n (%) Age <70 years (n = 1297) ge ≥70 years (n = 480) Age <75 years (n = 1571) Age ≥75 years (n = 206)
Diarrhoea 36 (2.8) 13 (2.7) 45 (2.9) 4 (1.9)
Nausea 29 (2.2) 4 (0.8) 30 (1.9) 3 (1.5)
Hypertension 15 (1.2) 8 (1.7) 23 (1.5) 0
Bleeding 17 (1.3) 4 (0.8) 18 (1.1) 3 (1.5)
Leucopenia 7 (0.5) 1 (0.2) 8 (0.5) 0
Infection 6 (0.5) 2 (0.4) 8 (0.5) 0
Proteinuria 5 (0.4) 2 (0.4) 5 (0.3) 2 (1.0)
Phlebitis/thrombosis/embolism 11 (0.8) 6 (1.3) 15 (1.0) 2 (1.0)